Annovis Bio Inc. - notizie pubblicate 175 - letture 3.702
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ANNOVIS BIO INC.
Annovis Bio Announces Launch of Proposed Public Offering - Form 8-K
Annovis bio announces launch of proposed public offering berwyn, pennsylvania, october 30, 2023 /business wire/ -- annovis bio, inc. (nyse: anvs) ("annovis"), a late-stag ...
ANNOVIS BIO INC.
Supplemental Prospectus - Form 424B5
Filed pursuant to rule 424(b)(5) registration no. 333-252625 prospectus supplement (to prospectus dated february 11, 2021) 1,250,000 shares of common stock warrants to purchase 1,2 ...
ANNOVIS BIO INC.
October 31, 2023Annovis Bio Announces Pricing of $7.5 Million Public Offering
Tue, 31 oct 2023 berwyn, pa.--(business wire)-- annovis bio, inc. (nyse: anvs) ("annovis"), a late-stage clinical drug platform company developing transformative therapie ...
ANNOVIS BIO INC.
Supplemental Prospectus - Form 424B5
Filed pursuant to rule 424(b)(5) registration no. 333-252625 the information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective reg ...
ANNOVIS BIO INC.
ANNOVIS BIO RECEIVES POSITIVE RECOMMENDATION TO CONTINUE PHASE 2/3 TRIAL OF BUNTANETAP FOR alzheimer’S DISEASE PATIENTS FROM THE INDEPENDENT DATA AND SAFETY MONITORING BOARD (DSMB) - Form 8-K
Annovis bio receives positive recommendation to continue phase 2/3 trial of buntanetap for alzheimer's disease patients from the independent data and safety monitoring board (dsmb) ...
ANNOVIS BIO INC.
October 30, 2023Annovis Bio Announces Launch of Proposed Public Offering
Mon, 30 oct 2023 berwyn, pa.--(business wire)-- annovis bio, inc. (nyse: anvs) ("annovis"), a late-stage clinical drug platform company developing transformative therapie ...
ANNOVIS BIO INC.
October 30, 2023Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
Mon, 30 oct 2023 berwyn, pa.--(business wire)-- annovis bio, inc. (nyse: anvs), announces the positive safety review by the data and safety monitoring board (dsmb) for its phase 2/ ...
ANNOVIS BIO INC.
October 24, 2023Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
Tue, 24 oct 2023 berwyn, pa.--(business wire)-- annovis bio, inc. (nyse: anvs), a late-stage clinical drug platform company developing transformative therapies to treat neurodegene ...
ANNOVIS BIO INC.
ANNOVIS BIO ANNOUNCES POSITIVE interim INDEPENDENT analysis For STATISTICAL POWER IN its Alzheimer’s study - Form 8-K
Annovis bio announces positive interim independent analysis for statistical power in its alzheimer's study october 12, 2023 pre-specified, blinded interim analysis for sample size ...
ANNOVIS BIO INC.
October 12, 2023Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
Thu, 12 oct 2023 berwyn, pa., oct. 12, 2023 (globe newswire) -- annovis bio, inc. (nyse: anvs) ("annovis" or the "company"), a clinical-stage drug platform comp ...
ANNOVIS BIO INC.
August 15, 2023Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Tue, 15 aug 2023 berwyn, pa.--(business wire)-- annovis bio, inc. (nyse: anvs), a late-stage clinical drug platform company developing transformative therapies to treat neurodegene ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti